Foundry Partners LLC Cuts Stock Position in Avanos Medical, Inc. (NYSE:AVNS)

Foundry Partners LLC decreased its holdings in Avanos Medical, Inc. (NYSE:AVNS) by 26.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 119,870 shares of the company’s stock after selling 43,160 shares during the quarter. Foundry Partners LLC owned 0.26% of Avanos Medical worth $1,908,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Vanguard Group Inc. boosted its position in Avanos Medical by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 5,339,778 shares of the company’s stock valued at $85,009,000 after buying an additional 19,476 shares during the period. William Blair Investment Management LLC raised its stake in shares of Avanos Medical by 2.1% in the fourth quarter. William Blair Investment Management LLC now owns 1,406,210 shares of the company’s stock valued at $22,387,000 after acquiring an additional 28,608 shares in the last quarter. Paradice Investment Management LLC boosted its holdings in Avanos Medical by 2.5% in the fourth quarter. Paradice Investment Management LLC now owns 1,293,198 shares of the company’s stock valued at $20,588,000 after purchasing an additional 30,949 shares during the period. Geode Capital Management LLC grew its stake in Avanos Medical by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 1,054,162 shares of the company’s stock worth $25,337,000 after purchasing an additional 16,065 shares in the last quarter. Finally, Tributary Capital Management LLC increased its holdings in Avanos Medical by 38.1% during the 4th quarter. Tributary Capital Management LLC now owns 893,008 shares of the company’s stock worth $14,217,000 after purchasing an additional 246,379 shares during the period. Institutional investors and hedge funds own 95.17% of the company’s stock.

Avanos Medical Trading Down 4.4 %

Shares of NYSE:AVNS opened at $13.42 on Friday. Avanos Medical, Inc. has a 52 week low of $13.25 and a 52 week high of $25.36. The company’s 50 day moving average is $15.48 and its two-hundred day moving average is $18.05. The company has a market cap of $617.13 million, a PE ratio of 39.46 and a beta of 1.15. The company has a current ratio of 2.22, a quick ratio of 1.46 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last posted its earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.40 by $0.03. The firm had revenue of $179.60 million for the quarter, compared to analyst estimates of $177.23 million. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. Equities analysts predict that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, SVP Kerr Holbrook sold 7,000 shares of Avanos Medical stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $15.25, for a total transaction of $106,750.00. Following the sale, the senior vice president now directly owns 82,047 shares in the company, valued at $1,251,216.75. This trade represents a 7.86 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 2.64% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Avanos Medical from a “hold” rating to a “buy” rating in a research note on Wednesday, March 19th.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.